Chemokine (C-X-C Motif) Ligand 13 (CXCL13) Kits ELISA

Mouse (Murine) Chemokine (C-X-C Motif) Ligand 13 (CXCL13) interaction partners

1. CXCL13, upregulated by peripheral inflammation, acts on CXCR5 on dorsal root ganglia neurons and activates p38, which increases Nav1.8 current density and further contributes to the maintenance of inflammatory pain.

2. CXCL13 acts on CXCR5 to increase p38 activation and further contributes to the pathogenesis of orofacial neuropathic pain

3. This study indicated that CXCL13 may be pathogenically involved in Clostridium difficile infection (CDI) and served as a potential new biomarker for diagnosis and prognosis in CDI.

4. CXCL13 has a role in directing B-lymphocyte migration

5. CXCL13 and CXCR5 contribute to orofacial pain via ERK-mediated proinflammatory cytokines production.

6. High glucose could inhibit osteogenic differentiation of mesenchymal stem cells by lncRNA AK028326 mediated down-regulation of CXCL13 expression.

7. Data demonstrate that CXCL13 is not essential in mounting effective peripheral humoral responses, but specifically promotes CNS accumulation of differentiated B cells.

8. overexpression of CXCL13 is associated with myasthenia gravis.

9. Deficiency in Cxcl13 or its receptor, Cxcr5, significantly attenuated benzo(a)pyrene-induced lung cancer in mice, demonstrating CXCL13's critical role in polycyclic aromatic hydrocarbon-induced lung carcinogenesis.

10. Blockade of CXCL13 significantly reduced urine protein, serum creatinine, and dramatically attenuated renal pathology injury in lupus nephritis in mice.

11. Results from this study suggest blockade of CXCL13 and BAFFR together may be an effective therapeutic strategy in preventing salivary hypofunction and reducing autoantibody titers and sialadenitis in patients with Sjogren's syndrome

12. findings reveal a neuronal/astrocytic interaction in the spinal cord by which neuronally produced CXCL13 activates astrocytes via CXCR5 to facilitate neuropathic pain.

13. Study reports a novel role of AK141205/CXCL13 as a regulator of osteogenic growth peptide-induced osteogenic differentiation of smooth muscle cells.

14. Data indicate that CXC chemokine CXCL13-responsive late transitional B cells are the initiating subset for the positive feedback loop.

15. Study demonstrates that microglia are an important source of CXCL13 production in the acutely inflamed brain, and in vitro experiments confirm that type-I IFN selectively inhibits microglial production of CXCL13 in a dose-dependent manner

16. Data suggest that Src homology 3 (SH3) protein interacting with NcK, 90 kDa (SPIN90)plays an important role in B cell immune responses through the regulation of chemokine CXCL13-mediated B cell migration.

17. mediates vaccine-induced immunity against tuberculosis

18. CXCL13 may be pathogenically involved in SS and may serve as a new marker and a potential therapeutic target.

19. CXCL13 is produced within lymphoid follicles of patients with COPD and is crucial for the formation of TLOs.

20. Late stage cathepsin C, CXCL13 and Ki-67 overexpression correlate with regional neuropathology in a bovine spongiform encephalopathy transgenic murine model.

Human Chemokine (C-X-C Motif) Ligand 13 (CXCL13) interaction partners

1. The levels of serum PTX3, vWf and CXCL13 increased in patients with Unstable Angina Pectoris.

2. The chemokine CXCL13 was the most upregulated cytokine across all idiopathic multicentric Castleman disease patients. Expression of CXCL13 was also significantly increased in iMCD lymph node germinal centers compared to controls in a stromal meshwork pattern.

3. Consistent with a previous study, CXCL13 is likely to be involved in SSc development, possibly regulating macrophage/B-cell interaction, Th17 cell infiltration and vasculopathy.

4. CXCL13 and CCL20 synergistically increased B-cell migration from peripheral blood of rheumatoid arthritis patients.

5. Breast cancer CD4, FOXP3, and CXCL13 contents were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR), and their influence on distant disease-free survival (DDFS) was examined using univariable and multivariable Cox regression and Kaplan-Meier estimates in the entire cohort and in selected molecular subgroups.

6. Applying a linearized cut-off of the CXCL13 concentration in the CSF which is dependent on the CSF cell count is a novel approach in the laboratory diagnosis of Lyme neuroborreliosis.

7. CXCR5 drove migration toward its ligand, CXCL13, and probed for interactions with several candidates using flow cytometry-based Forster resonance energy transfer.

8. Study shows that SOX4 is a key transcription factor for CXCL13 production in human CD4+ T cells under inflammatory conditions. SOX4 is significantly upregulated in synovial CD4+ T cells, when compared with blood CD4+ T cells, from patients with rheumatoid arthritis.

9. CXCL13 is elevated in cerebrospinal fluid in children with Lyme neuroborreliosis.

10. We found a strong association of CXCL13 rs355689*C allele with essential hypertension under additive (OR 0.56, PFDR = 0.008) and dominant (OR 0.41, PFDR 4.38 x 10- 4) genetic model. Our results indicate that CXCL13 rs355689 polymorphism is strongly associated with essential hypertension in the ethnic group of Tatars from Russia.

11. High CXCL13 expression was associated with larger tumor diameter and shorter OS. By multivariate analysis, CXCL13 expression was associated with OS independently from clinicopathological factors.

12. IL-17 enhances the migration of B cells during asthma by inducing CXCL13 chemokine production in structural lung cells.

13. the findings of the present study indicated that the noninvasive investigation of urinary CXCL13/Cr may be valuable for the detection of AR, particularly antibodymediated rejection . In addition, high urinary CXCL13/Cr levels predicted a poor response to steroid treatment and compromised graft function

14. CXCL13 seems to be a useful marker of disease activity in systemic lupus erythematosus, but not in cutaneous lupus erythematosus or chronic cutaneous lupus erythematosus.

15. Serum level of CXCL13 is associated with disease activity in systemic lupus erythematosus but does not seem to be a biomarker for arthritis.

16. Serum CXCL13 positivity was found to be associated with oral symptoms, ocular signs and hyperglobulinemia in Asian Indian patients with primary Sjogren's syndrome.

17. we found that CXCL13 indeed has a high sensitivity and specificity for diagnosing LNB, which means that it can be used as a new diagnostic biomarker for the diagnosis of LNB.

18. the elevated concentrations of CXCL13, CXCL8, and CXCL10 or their increasing CSF/serum ratios may be potential biomarkers of neurosyphilis

19. CXCL13 is a highly sensitive and specific CSF marker that helps to differentiate Lyme neuroborreliosis from other central nervous system disorders in children.

20. Study suggested that maternal rs355687 variant in CXCL13 gene was associated with decreased risk of HBV intrauterine infection compared to those with CC genotypes.